title: [Undesirable effects and interaction to angiotensin converting enzyme inhibitors therapy].
abstract: By their intervention upon the mechanisms regulating the vascular tone, renal plasma flow and direct actions of chemical structures, angiotensin-converting enzyme (ACE) inhibitors may determine undesirable effects. These effects formed the object of a 5-year retrospective study (1995-1999) carried out at the IIIrd Medical Clinic of Iasi. During this interval ACE inhibitors were administrated to 2178 patients with hypertensive and coronary disorders or heart failure of various causes. Different generations of ACE inhibitors were used, but captopril, enalapril and lysinopril were the most commonly administered. Undesirable effects were recorded in 161 patients (7.3%). The following side-effects, single or associated, were recorded: 38 patients (23.6%) had increasing blood pressure proportional with ACEI dose, 80 patients (49.7%) had decreasing blood pressure at low doses ACEI, 23 patients (14.4%) had kidney failure, 2 patients (1.2%) had both increasing blood pressure and kidney failure, 3 patients (1.9%) had both decreasing blood pressure and kidney failure, 6 patients (3.8%) had dry cough, one patient (0.6%) had kidney failure with decrease blood pressure and allergic dermatitis, 4 patients (2.4%) had allergic dermatitis, and 4 patients (2.4%) had headache, vertigo, paresthesia.
  
  
  CONCLUSIONS
  The treatment with ACE inhibitors has to be carefully initiated under strict clinical and biological monitoring, preferably in hospital setting. No drug associations that favor the undesirable effects of ACE inhibitors were reported.
authors.affiliation: Clinica a III-a Medicală Cardiologică I. Enescu, Facultatea de Medicină, Universitatea de Medicină şi Farmacie Gr.T. Popa Iaşi.
authors.forename: Simona Daniela
authors.initials: SD
authors.lastname: Ionescu
authors.forename: V
authors.initials: V
authors.lastname: Sandru
authors.forename: Elena
authors.initials: E
authors.lastname: Leuciuc
authors.forename: Paloma
authors.initials: P
authors.lastname: Manea
authors.forename: Alina
authors.initials: A
authors.lastname: Burdujan
authors.forename: Svetlana
authors.initials: S
authors.lastname: Tovarniţchi
authors.forename: A
authors.initials: A
authors.lastname: Cosovanu
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D002216:Captopril / Q000009:adverse effects* / Q000627:therapeutic use; D003875:Drug Eruptions / Q000209:etiology; D004347:Drug Interactions; D004656:Enalapril / Q000009:adverse effects* / Q000627:therapeutic use; D006261:Headache / Q000139:chemically induced; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007022:Hypotension / Q000139:chemically induced; D017706:Lisinopril / Q000009:adverse effects* / Q000627:therapeutic use; D012189:Retrospective Studies; D014717:Vertigo / Q000139:chemically induced
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D004656:Enalapril; D002216:Captopril; D017706:Lisinopril